People with risk of diabetes or celiac disease-intolerance to gluten-may follow a normal diet, thanks to a new drug developed by the University of Baltimore and the company Alba Thera-peutics, USA.Known as AT 1001. The drug acts on the zonulina, a protein that regulates intestinal permeability and appears at higher levels in diabetics and Celiacs.
It is expected that the AT 1001 is marketed in 2006.
On the other hand, diabetics could forget the invecciones with a new device from the U.S. company Ara paradigms. allowing them to inhale the hormone.
No comments:
Post a Comment